Pseudoprogressions in Oncolytic Therapy: Alerts and Regulations Needed
Pseudoprogression (PsP) refers to either visually observed or imaging-detected tumor enlargement followed by regression after cancer therapies. Characterized by robust localized immune infiltration, PsP is most commonly seen in immunotherapies, with an occurrence rate of around 10% [1]. However, there was limited discussion of oncolytic therapy-related PsP. We argue that PsP is a commonly encountered phenomenon in oncolytic virotherapy, warranting increased attention during assessments in clini...
- DOWNLOAD
- FULL-TEXT
- DOI: 10.5281/zenodo.14878808
- 47 Views
- 43 Downloads